Recursion Pharmaceuticals, Inc. (RXRX)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Recursion Pharmaceuticals, Inc. (RXRX) is down 11.7% since the beginning of the year. At $4 per share, RXRX is trading 49.7% below its 52-week high of $7. Investors who bought $1,000 worth of RXRX shares 5 years ago would now be looking at an investment worth $127.

Recursion Pharmaceuticals, Inc. (RXRX) has returned -11.74% so far this year and -17.39% over the past 12 months.

Based on dividend-adjusted daily data since Apr 16, 2021, RXRX's average daily return is 0.00%, while the average monthly return is -0.83%.

Historically, 41% of months were positive and 59% were negative. The best month was Jul 2023 with a return of +89.0%, while the worst month was Aug 2023 at -38.4%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 11 months.

On a daily basis, RXRX closed higher 47% of trading days. The best single day was Jul 12, 2023 with a return of +78.2%, while the worst single day was Mar 4, 2022 at -21.1%.

Recursion Pharmaceuticals, Inc. has an annualized alpha of -26.78%, beta of 2.32, and R2 of 0.17 versus S&P 500 Index. Calculated based on daily prices since April 19, 2021.

• This stock participated in 194.14% of S&P 500 Index downside but only 9.65% of its upside - more exposed to losses than it benefited from rallies.
• R2 of 0.17 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

RXRX ranks 32 for risk / return — below 32% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.

The table below present risk-adjusted performance metrics for Recursion Pharmaceuticals, Inc. (RXRX) and compare them to S&P 500 Index.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Recursion Pharmaceuticals, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Recursion Pharmaceuticals, Inc. was 93.13%, occurring on Mar 30, 2026. The portfolio has not yet recovered.

The current Recursion Pharmaceuticals, Inc. drawdown is 91.27%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Recursion Pharmaceuticals, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Recursion Pharmaceuticals, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.